Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa
Status:
Recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group phase 1b study to
evaluate AT193 in approximately 40 participants with HS. The treatment period will be 8 weeks
followed by a 2-week nontreatment follow-up. The primary objective of this study is to
evaluate the safety and tolerability of AT193. The secondary objectives of this study are to
evaluate the preliminary efficacy in the treatment of HS.